Navigation Links
PRA Participates in Landmark Alzheimer's Prevention Clinical Trial
Date:7/24/2012

RALEIGH, N.C., July 24, 2012 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that it is participating in a groundbreaking Alzheimer's disease study that could lead to treatments delaying or even preventing the emergence of symptoms in people destined to develop the disease because of their genetic background. The clinical trial is a collaborative effort involving the Banner Alzheimer's Institute (BAI); Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY); the University of Antioquia in Colombia; and the National Institutes of Health (NIH). 

The trial will include about 300 participants in Colombia, home to a kindred of nearly 5,000 people who share a rare genetic mutation that triggers Alzheimer's symptoms at an early age. A smaller number of individuals in the United States will also participate. The Phase IIa trial will utilize Genentech's investigational drug crenezumab. This humanized monoclonal antibody targets amyloid beta, a protein thought by many scientists to play a key role in the development of the disease.

"This study has the potential to change patients' lives by shifting the research paradigm in Alzheimer's from treatment to early prevention," said Kent Thoelke, PRA's Executive Vice President of Scientific and Medical Affairs. "PRA and its specialty neurosciences group are proud to be involved with this landmark program and to be working with leaders in the field of Alzheimer's research like Banner Alzheimer's Institute and Genentech."

The prevention trial was recently announced by BAI, Genentech and NIH at the unveiling of the National Plan to Address Alzheimer's Disease. The federal plan aims to develop effective treatment and prevention strategies by the year 2025 by increasing research funding, training health professionals and improving public-private partnerships.

About PRA
PRA is transforming clinical trials through our people, innovation and transparency. PRA prov
'/>"/>

SOURCE PRA
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Misonix Participates In Cleveland Spine Review
2. BlackStratus participates in Joint FDA-ISPE CGMP Conference
3. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
4. President Obama Signs Landmark Accessible Prescription Drug Label Bill
5. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
6. Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant
7. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
8. Berg Pharma launches clinical trial on BPM 31543 for prevention of chemotherapy-induced alopecia (CIA)
9. Joslin Diabetes Center Convenes Leaders in Diabetes Prevention, Treatment, Payment, Education and Research at Diabetes Innovation 2012
10. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
11. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  InnoPharma, Inc. today ... 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada.  ... and disturbed behaviors in patients with schizophrenia or bipolar ... generic injectable drug, InnoPharma has entered into an agreement ... Canada will make, use, sell, market and distribute ...
(Date:7/30/2014)... Cynosure, Inc. (NASDAQ: CYNO ... non-invasive and minimally invasive applications, today announced that the Board ... and Chief Financial Officer Timothy W. Baker to ... will continue to serve as CFO and will take the ... Chairman and Chief Executive Officer. "Tim has ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014 /PRNewswire/ ... ) announced today that an article based on post-hoc analyses ... "Early Weight Loss While on Lorcaserin, Diet, and Exercise as ... in the online issue of Obesity , the official ... these analyses was to identify whether there is an early ...
Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Mass., Nov. 17 Decision Resources, one of the world,s ... finds that, driven by the continued dominance of opioids that ... cancer pain drug market will increase from $2.3 billion in ... France, Germany, Italy, Spain, the United Kingdom and Japan. , ...
... , DURHAM, N.C., Nov. 17 Oxygen ... the company has begun shipping Dermacyte(TM) Oxygen Concentrate Gel ... The shipments, which are going out today, cover orders ... milestone event for our company - actually shipping a ...
Cached Medicine Technology:The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018 2Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2
(Date:7/30/2014)... 2014 Good Neighbor Community Services ... upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , In this segment, ... Services’ vision to redefine the traditional approach to ... services. Through passion, innovation, determination, excellence, and collaboration, ...
(Date:7/30/2014)... SF Cable, distributor of the highest ... on the internet with guaranteed customer satisfaction announces the ... two colors. These lightning cords are MFI certified to ... quality SF Cable Lightning to USB Cables ... faster charging and syncing. Compatible with the iPhone 5S/5C/5 ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery ... Carmel office on July 30th. After months of planning, ... to the state-of-the-art suite, located only steps away from ... allow for one-on-one patient comfort, shorter wait times, and ... Dr. Hamilton’s new office-suite will continue to provide the ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis and confirmed that many suffer psychological and physical symptoms long ... , a UCLA team led by Dr. Brennan Spiegel interviewed patients in great detail about the symptoms they experience weeks, months or ...
(Date:7/30/2014)... York (PRWEB) July 30, 2014 As ... http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continues to grow, Bernstein ... voice to those calling for a ban on uterine ... Debra Valverde was diagnosed with leiomyosarcoma following a hysterectomy ... a year of her diagnosis, the aggressive cancer had ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
... to Better ... of Treatment Options, WASHINGTON, Nov. 2 Today, ... organization for interventional cardiology, announced the,launch of Seconds Count, ... for an authoritative resource about cardiovascular disease and,treatment. The ...
... Kensey Nash Corporation,(Nasdaq: KNSY ) today announced ... Coherence Domain Reflectometry Guidewire, from Lawrence,Livermore National Security, ... to its chronic total occlusion (CTO) platform.,The patent ... it to sense locations, thickness, and structure of ...
... CPR, assistance, measuring pain medication effectiveness, improving cancer ... ... A novel way to treat cancer,has won the top honor at the ... Fame Foundation. Ian,Cheong of Johns Hopkins University was announced as the grand ...
... of the time,that sales people should be spending with the ... Pharmaceutical sales directors agree the answer is ,too much time, ... - or 6 weeks per rep,per year - is unnecessary ... recent research study by Best Practices, LLC. But yet,understanding and ...
... LAWRENCE, Mass., Nov. 2 NxStage Medical, Inc.,(Nasdaq: ... portable,kidney dialysis machine, today announced its financial results for ... the third quarter of 2007 were $11.6 million, compared ... increase of 111%. Revenues in,the chronic home dialysis market ...
... demonstrates >99% mean decrease in HCV RNA ... with no serious adverse events-, PRINCETON, ... results of a 14-day Phase 1 multiple ascending,dose monotherapy study of ... being presented as a "late-breaker" abstract at,the 58th Annual Meeting of ...
Cached Medicine News:Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 3Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 3Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 2Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 3Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 4Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 5Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:NxStage Medical Reports Third Quarter 2007 Results 2Health News:NxStage Medical Reports Third Quarter 2007 Results 3Health News:NxStage Medical Reports Third Quarter 2007 Results 4Health News:NxStage Medical Reports Third Quarter 2007 Results 5Health News:NxStage Medical Reports Third Quarter 2007 Results 6Health News:NxStage Medical Reports Third Quarter 2007 Results 7Health News:NxStage Medical Reports Third Quarter 2007 Results 8Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 3Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 4Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 5
... ART Aerosol Resistant Tips offer a ... ART Tips are designed for applications such ... studies. In addition, ART Tips are excellent ... and forensic studies. ART Tips prevent aerosol ...
... Binding, Graduated Pipet Tips - 2l - 200l. ... referenced. Produced & packaged completely by automation. RNAse ... packaged 96 tips/rack and 10 racks/cs. AVR2 is ... racks/cs. AVR3 is the Stacked Rack packaged 96 ...
... orifice tip, the Finntip Wide is designed ... macromolecules like genomic DNA. This tip eliminates ... It is excellent for use with extremely ... inside diameter of the orifice is 1.1 ...
... been designed to optimize the accuracy and ... tip products is widely recognized by customers ... been extended over the years and now ... special tips including filter tips, certified pure ...
Medicine Products: